RhDNase I aerosol deposition and related factors in cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 156, Issue 5, 1997, Pages 1662-1668

  Diot, Patrice ^b   Palmer, Lucy B ^b   Smaldone, Arlene ^b   Decelie Germana, Joan ^b   Grimson, Roger ^b   Smaldone, Gerald C ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA; HUMAN SERUM ALBUMIN TC 99M; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AEROSOL; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG DEPOSIT; MALE; PHARYNX; PRIORITY JOURNAL; SCINTILLATION CAMERA;

EID: 0030656515     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.156.5.9604093     Document Type: Article

References (21)

1. Collins, F. S. 1992. Cystic fibrosis: molecular biology and therapeutic implications. Science 256:774-779.
2. Chernick, W. S., and G. J. Barbero. 1959. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 24:739-745.
3. Smith, A. L., G. Redding, C. Doershuk, D. Goldman, R. Gore, B. Hilman, M. Marks, R. Moss, B. Ramsey, T. Rubio, R. H. Schwartz, M. J. Thomassen, J. Williams-Warren, A. Weber, R. W. Wilmott, H. D. Wilson, and R. Yogev. 1988. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J. Pediatr. 112:547-554.
4. Shak, S., D. J. Capon, R. Hellmiss, S. A. Masters, and C. L. Baker. 1990. Recombinant human Dnase reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. U.S.A. 87:9188-9192.
5. Zahm, J. M., S. Girod de Bentzmann, F., Deneuville, C. Perrot-Minnot, A. Dahadie, F. Pennaforte, M. Roussey, S. Shak, and E. Puchelle, 1995. Dose-dependent in vitro effect of recombinant human Dnase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur. Respir. J. 8:831-836.
6. Ramsey, B. W., S. J. Astley, M. L. Aitken, W. Burke, A. A. Coli, H. L. Dorkin, J. D. Eisenberg, R. L. Gibson, J. R. Harwood, D. V. Schidlow, R. W. Wilmott, M. F. Wohl, S. Shak, H. Fuchs, and A. Smith. 1993. Efficacy and safety of short-term recombinant human deoxyribonuclease in patients with cystic fibrosis. Am. Rev. Respir. Dis. 148: 145-151.
7. Ranasinha, C., B. Assoufi, D. Christiansen, H. Fuchs, D. Empey, H. Geddes, and M. Hodson. 1993. Efficacy and safety of short-term administration of aerosolized recombinant human Dnase 1 in adults with stable stage cystic fibrosis. Lancet 342:199-202.
8. Fuchs, H. J., D. S. Burowitz, D. H. Christiansen, E. M. Morris, M. L. Nash, H. W. Ramsey, B. J. Rosenstein, A. L. Smith, and M. E. Wohl. 1994. Effect of aerosolized recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331:637-643.
9. Shah, P. L., S. F. Scott, H. J. Fuchs, D. M. Geddes, and M. F. Hodson. 1995. Medium term treatment of stable stage cystic fibrosis with recombinant human Dnase 1. Thorax 50:333-338.
10. Hodson, M. F., 1995. Aersolized dornase alfa (rhDNase) for therapy of cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:S70-S74.
11. Ilowite, J. S., J. D. Gorvoy, and G. C. Smaldone. 1987. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 136:1445-1449.
12. Diot, P., B. Rivoire, A. Le Pape, E. Lemarie, D. Dire, Y. Furet, M. Breteau, and G. C. Smaldone. 1995. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur. Respir. J. 8:1263-1268.
13. Cipolla, D., I. Gonda, and S. Shire. 1994. Characterization of aerosols of human recombinant deoxyribonuclease (rhDNase) generated by jet nebulizers. Pharm. Res. 11:491-498.
14. Smaldone, G. C. 1991. Drug delivery via aerosol systems: concept of "aerosol inhaled." J. Aerosol Med. 4:229-236.
15. Smaldone, G. D., J. Fuhrer, R. T. Steigbigel, and M. McPeck. 1991. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am. Rev. Respir. Dis. 143:727-737.
16. O'Riordan, T. G., A. Iacono, R. J. Keenan, S. R. Duncan, G. J. Burckart, B. P. Griffith, and G. C. Smaldone. 1994. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am. J. Respir. Crit. Care Med. 151:516-521.
17. Smaldone, G. C., R. J. Perry, and D. G. Deutsch. 1988. Characteristics of nebulizers used in the treatment of AIDS-related Pneumocystic carinii pneumonia. J. Aerosol Med. 1:113-126.
18. O'Riordan, T. G., M. J. Greco, and G. C. Smaldone. 1992. Nebulizer function during mechanical ventilation. Am. Rev. Respir. Dis. 145: 1117-1122.
19. Smaldone, G. C., R. J. Perry, W. D. Bennett, M. S. Messina, J. Zwang, and J. Ilowite. 1988. Interpretation of "24 hour retention" in studies of mucociliary clearance. J. Aerosol Med. 1:11-20.
20. Itoh, H., Y. Ishii, H. Maeda, G. Todo, K. Torizuka, and G. C. Smaldone. 1981. Clinical observations of aerosol deposition in patients with airways obstruction. Chest 80 (Suppl.):837-839.
21. Smaldone, G. C., and M. S. Messina. 1985. Flow-limitation, cough, and patterns of aerosol deposition in humans. J. Appl. Physiol. 59:515-520.